

80.2. Pediatric Hodgkin and Non-Hodgkin Lymphomas: Pediatric Non-Hodgkin Lymphomas

Authors

Michael P. Link, Elaine S. Jaffe, John P. Leonard

Emerging Prognostic Factors for Clinical Care

Factor	Definition	Clinical significance	Level of evidence
Cytogenetics	Identification of specific cytogenetic abnormalities in malignant cells	Specific rearrangements have prognostic significance, e.g., 13q deletion.	I
Molecular characterization of blast cells in lymphoblastic lymphoma	Immunophenotype/molecular phenotypes analogous to those defined in ALL	By analogy to ALL, specific molecular phenotypes have prognostic significance.	I
International Pediatric non-Hodgkin lymphoma staging system	Recently, a multidisciplinary expert panel proposed a revised INHLSS to address some of the shortcomings of the St. Jude staging classification. ¹	Pending further study. As this classification gains more acceptance, AJCC will consider its use in the future for uniformity in management of children with NHL and will facilitate comparisons of study results.	II

Risk Assessment Models

The AJCC recently established guidelines that will be used to evaluate published statistical prediction models for the purpose of granting endorsement for clinical use.² Although this is a monumental step toward the goal of precision medicine, this work was published only very recently. Therefore, the existing models that have been published or may be in clinical use have not yet been evaluated for this cancer site by the Precision Medicine Core of the AJCC. In the future, the statistical prediction models for this cancer site will be evaluated, and those that meet all AJCC criteria will be endorsed.

80.2. Pediatric Hodgkin and Non-Hodgkin Lymphomas: Pediatric Non-Hodgkin Lymphomas

Recommendations for Clinical Trial Stratification

The authors have not provided any recommendations for clinical trial stratification at this time.

Bibliography

1. Rosolen A, Perkins SL, Pinkerton CR, et al. Revised International Pediatric Non-Hodgkin Lymphoma Staging System. *J Clin Oncol*. 2015;33(18):2112-2118.
2. Kattan MW, Hess KR, Amin MB, et al. American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. *CA: a cancer journal for clinicians*. 2016.